OncoMed Pharmaceuticals (OMED) Earns Daily News Impact Rating of 0.31
Media stories about OncoMed Pharmaceuticals (NASDAQ:OMED) have trended positive recently, Accern reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. OncoMed Pharmaceuticals earned a coverage optimism score of 0.31 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.9004365876554 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Traded 24.2% Above Its 50 Day Moving Average – First News 24 (firstnewspaper24.com)
- Indicator Watch on Shares of OncoMed Pharmaceuticals Inc (OMED) – Bulletin News (orobulletin.com)
- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Sees Significantly Lower Trading Volume – Highlight Press (highlightpress.com)
- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Experiences Lighter than Usual Trading Volume (highlightpress.com)
- OncoMed Pharmaceuticals, Inc. (OMED) Receives Consensus Rating of “Hold” from Analysts (americanbankingnews.com)
OncoMed Pharmaceuticals (OMED) opened at 4.60 on Thursday. The firm’s market cap is $173.10 million. OncoMed Pharmaceuticals has a 52-week low of $2.91 and a 52-week high of $12.58. The company’s 50 day moving average is $4.00 and its 200-day moving average is $5.18.
OncoMed Pharmaceuticals (NASDAQ:OMED) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.10. The firm had revenue of $6.20 million for the quarter, compared to analysts’ expectations of $6.08 million. The business’s quarterly revenue was down 7.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.91) EPS. On average, equities analysts predict that OncoMed Pharmaceuticals will post ($1.85) EPS for the current fiscal year.
OMED has been the topic of a number of recent analyst reports. HC Wainwright dropped their price target on shares of OncoMed Pharmaceuticals from $9.00 to $6.00 and set a “buy” rating on the stock in a research report on Monday, May 15th. Jefferies Group LLC restated a “buy” rating and issued a $5.00 price target on shares of OncoMed Pharmaceuticals in a research report on Sunday, July 9th. Piper Jaffray Companies set a $5.00 price target on shares of OncoMed Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday, July 10th. Finally, ValuEngine downgraded shares of OncoMed Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. One analyst has rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company’s stock. OncoMed Pharmaceuticals has a consensus rating of “Hold” and an average price target of $8.00.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
Receive News & Stock Ratings for OncoMed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoMed Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.